Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 57Carcinoma, Non-Small-Cell Lung 53Carcinoma, Renal Cell 39Neoplasm Metastasis 22Lung Neoplasms 22Carcinoma, Hepatocellular 21Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Colorectal Neoplasms 17Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 13Prostatic Neoplasms 11Hodgkin Disease 11Brain Neoplasms 10Urinary Bladder Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Skin Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Sarcoma 6Carcinoma, Merkel Cell 6Carcinoma, Basal Cell 6Uveal Melanoma 5

Interventions

varlilumab 1Nivolumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphomatoid Granulomatosis × Nivolumab × 90 days × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡